8-K: Silexion Therapeutics Executes 1-for-9 Reverse Stock Split and Adjusts Warrants

Silexion Therapeutics has completed a 1-for-9 reverse stock split and adjusted its warrants, effective November 29, 2024.

Summary

• Silexion Therapeutics has implemented a 1-for-9 reverse stock split of its ordinary shares.
• The reverse stock split was approved by shareholders at a reconvened extraordinary general meeting on November 19, 2024.
• The reverse split became effective after the close of trading on November 27, 2024.
• The number of authorized shares decreased from 200,000,000 to 22,222,222, while the par value increased from $0.0001 to $0.0009 per share.
• The company also adjusted its warrants, decreasing the number of shares issuable upon exercise to 1/9th of a share and increasing the exercise price to $103.50 per share.
• Fractional shares resulting from warrant exercises will be rounded up to the nearest whole share.
• Trading on a split-adjusted basis commenced on November 29, 2024, under the existing ticker symbol SLXN.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing a necessary corporate action to maintain listing compliance. While not inherently positive, it is a standard procedure for companies in this situation.

Positives

• The reverse stock split is intended to help the company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market.

Risks

• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements.
• The adjusted warrant terms may impact the attractiveness of the warrants to investors.

Future Outlook

The company's ordinary shares will continue to trade on the Nasdaq Global Market under the ticker symbol SLXN on a split-adjusted basis.

Management Comments

• The Board of Directors determined that the reverse stock split was an effective means of regaining compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

Industry Context

Reverse stock splits are a common strategy for companies to regain compliance with minimum listing requirements on exchanges like Nasdaq, often after a period of declining share price.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies facing delisting from major exchanges due to low share prices.
• Many biotech companies, particularly those in the early stages of development, have used reverse stock splits to maintain their listing status.
• For example, companies like Cassava Sciences and Ocugen have also undertaken reverse stock splits to meet Nasdaq's minimum bid price requirements.
• The 1-for-9 ratio is a relatively common ratio for reverse stock splits, although the specific ratio is determined by the company's needs and share price.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant immediately after the split.
• Warrant holders will have their warrants adjusted to reflect the reverse stock split, potentially impacting their exercise value.

Next Steps

• The company will continue to trade on the Nasdaq Global Market under the ticker symbol SLXN on a split-adjusted basis.
• Warrant holders will have their holdings adjusted to reflect the reverse stock split.

Key Dates

Keywords

reverse stock split, warrant adjustment, ordinary shares, share consolidation, Nasdaq, SLXN, SLXNW